Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
- Sponsor
- Lymphoma Study Association
- Study ID
- NCT00169143
- Phase
- PHASE2
- Status
- Completed
Conditions
- Untreated CD20-positive Large B-cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 61 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab + ACVBP regimen plus Pegfilgrastim — DRUG
- Autologous stem cell transplant — PROCEDURE
Study Details
Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international prognostic index (Aa-IPI).
Key Dates
- First listed
- Sep 15, 2005
- Start date
- May 31, 2004
- Status verified
- Aug 2018
- Primary completion
- Jan 31, 2007
- Completion
- Jan 31, 2007
Study Design
- Enrollment
- 60 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To evaluate the optimal combined dose intensity of the drug regimen